Tag Archives: Eli Lilly

Behind the China Bribery Scandals

The last few weeks have seen the media swamped with stories about the rampant bribery clawing the pharmaceutical industry in China. Big names were engulfed in the scandal, including GSK, AstraZeneca, Sanofi, Novartis, Eli Lilly, Novo Nordisk and UCB amongst others. Last month, four GSK executives were put under investigation for allegedly paying up to […]
Posted in Emerging Markets, Global, Guest Blog | Also tagged , , , , , , , , | Leave a comment

The Curious Case Of AstraZeneca v. ACE

by Mike Kelly and Andrew Dupre Insurance contracts are a language game that must be played very carefully, as AstraZeneca learned. From 2003 to 2012, AstraZeneca Plc was locked in one of the largest mass tort litigations in the United States, defending its blockbuster second generation atypical antipsychotic product Seroquel from allegations of failure-to-warn of […]
Posted in compliance, Europe, Guest Blog, leadership, Legal, Marketing, Regulatory, Safety, Sales, Strategy | Also tagged , , , , , , , | Leave a comment

Pipeline Report Preview

Posted in Advertising, Biotech, Europe, FDA, Gene therapy, Global, IP, R&D, Regulatory, Strategy, Video | Also tagged , , , , , , , , | Leave a comment

Adaptive Trial Design and Combo Drugs Needed in Alzheimer’s

FDA’s head of neurology products told industry execs at the Prix Galien Forum that the agency is open to alternative clinical trial designs in Alzheimer’s disease, and would like to see more combination products in clinical testing.
Posted in Agency Insight, FDA, R&D, Regulatory | Also tagged , | Leave a comment

Diabetes Drug Launch 2012: Tip-tops and Promo-flops

With Halloween candy flooding the shelves in pharmacies across the nation, it’s only appropriate that we turn the conversation toward an ever-growing drug market and therapeutic area: diabetes.
Posted in Advertising, E-Media, FDA, Marketing, Meetings, Strategy | Also tagged , , , , | 1 Comment
  • Categories

  • Meta